- Home
- CTNM vs ENTA Comparison
CTNM vs ENTA Comparison
Compare CTNM & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- ENTA
- Stock Information
- Founded
- CTNM 2009
- ENTA 1995
- Country
- CTNM United States
- ENTA United States
- Employees
- CTNM N/A
- ENTA N/A
- Industry
- CTNM
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- CTNM
- ENTA Health Care
- Exchange
- CTNM Nasdaq
- ENTA Nasdaq
- Market Cap
- CTNM 174.6M
- ENTA 164.6M
- IPO Year
- CTNM 2024
- ENTA 2013
- Fundamental
- Price
- CTNM $7.38
- ENTA $8.00
- Analyst Decision
- CTNM Strong Buy
- ENTA Strong Buy
- Analyst Count
- CTNM 4
- ENTA 4
- Target Price
- CTNM $22.50
- ENTA $20.75
- AVG Volume (30 Days)
- CTNM 196.1K
- ENTA 172.2K
- Earning Date
- CTNM 08-05-2025
- ENTA 08-11-2025
- Dividend Yield
- CTNM N/A
- ENTA N/A
- EPS Growth
- CTNM N/A
- ENTA N/A
- EPS
- CTNM N/A
- ENTA N/A
- Revenue
- CTNM N/A
- ENTA $64,806,000.00
- Revenue This Year
- CTNM N/A
- ENTA N/A
- Revenue Next Year
- CTNM N/A
- ENTA $4.05
- P/E Ratio
- CTNM N/A
- ENTA N/A
- Revenue Growth
- CTNM N/A
- ENTA N/A
- 52 Week Low
- CTNM $3.35
- ENTA $4.09
- 52 Week High
- CTNM $20.55
- ENTA $13.43
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- ENTA 59.48
- Support Level
- CTNM N/A
- ENTA $6.45
- Resistance Level
- CTNM N/A
- ENTA $7.73
- Average True Range (ATR)
- CTNM 0.00
- ENTA 0.51
- MACD
- CTNM 0.00
- ENTA 0.05
- Stochastic Oscillator
- CTNM 0.00
- ENTA 83.33
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.